Radioimmunotherapy in limited-stage diffuse large B-cell lymphoma

Patients with limited-stage aggressive B-cell lymphoma without adverse risk factors are generally cured when treated by short-term therapy, with overall survival (OS) at 10 years ranging from 94% to 97% (1,2). However, limited-stage diffuse large B-cell lymphoma (DLBCL) patients with adverse risk factors including stage II disease, age >60 years, elevated serum lactate dehydrogenase (LDH), and poor performance status have a relatively unfavorable outcome, with a 5-year OS of 50% to 77% and a 10-year OS of 0% to 50%, and treatment optimization is needed for this subtype patients (1-4).